Investors

Corporate Profile
We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases.

Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs. Our initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, by depriving tumors of nutrients necessary for their survival, which is referred to as tumor starvation.
Stock Quote
ERYP.PA (Common Stock)
ExchangeParis (Euro)
Price€28.00
Change (%) Stock is Up 5.30 (23.35%)
Volume1,626,913
Data as of 03/29/17 5:36 p.m. ET
Refresh quote
Recent NewsMore >>
DateTitle  
27-Mar-2017ERYTECH Reports Positive Phase 2b Data for eryaspase for the Treatment of Metastatic Pancreatic Cancer
Conference call and webcast on Tuesday, March 28th at 14:30 pm CET/08:30 am EDT Primary progression-free survival (PFS) and overall survival (OS) endpoints met in patients with low asparagine synthetase (ASNS) Statistically significant improvement of OS and PFS in the entire patient population LYON, France--(BUSINESS WIRE)--Mar. 27, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERY... 
 Printer Friendly Version
23-Mar-2017ERYTECH Collaborates with Fox Chase Cancer Center to Advance Its Platform in the Field of Rare Metabolic Disorders
LYON, France--(BUSINESS WIRE)--Mar. 23, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris - ERYP), a French clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases, today announced that it has entered into a research collaboration with Fox Chase Cancer Center (FCCC) to advance the pre-clinical development of the Company’s erymethionase program for h... 
 Printer Friendly Version
20-Mar-2017ERYTECH Presents New Preclinical Anti-Tumor Data on Erymethionase at AACR 2017
LYON, France--(BUSINESS WIRE)--Mar. 20, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY), a French clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug substances inside red blood cells, today announced the presentation of new anti-tumor data supporting the Company’s preclinical product e... 
 Printer Friendly Version
07-Mar-2017ERYTECH to Present Preclinical Results Supporting Immunotherapy Potential of ERYMMUNE Platform at Two Upcoming Medical Meetings
LYON, France--(BUSINESS WIRE)--Mar. 7, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY), a French clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug substances inside red blood cells, today announced the presentation of encouraging preclinical data supporting the Company’s ERYMMUNE prog... 
 Printer Friendly Version
Upcoming EventsMore >>
DateTitle
05/18/17
First Quarter 2017 Financial Results and Business Update: Press Release: Thursday, May 18, 2017 (after market)
05/19/17 3:00 p.m. CET
First Quarter 2017 Financial Results and Business Update:Conference Call
06/27/17 9:30 a.m. CET
General Meeting of Shareholders
LocationParis, France
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Erytech Pharma SA posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources